NANOEMULSIONS FOR PROSTRATE CANCER THERAPY: AN OVERVIEW
The objective of this review is to focus the inferences of low/poor bioavailability and lack of dose proportionality for the oral delivery of drugs in prostate
cancer therapy. To overcome such problems, various formulation strategies has been reported including various methods for the use of surfactants,
cyclodextrins, solid dispersions, micronization, permeation enhancers, and lipids. Flutamide is an antiandrogen drug and used for the therapy of prostate cancer. The flutamide drug is having limited clinical application due to its poor water solubility and needs enhancement of its dissolution rate in simulated gastric fluids. The lipid-based formulations such as nanoemulsion have been shown to improve the solubility and oral absorption of lipophilic drugs. To conclude, this article emphasizes the various approaches of nanoemulsion based formulation for prostate cancer therapy.
2. Solans C, Izquierdo P, Nolla J, Azemar N, Garcia-Celma MJ. Nano-emulsions. Curr Opin Colloid Interface Sci 2005;10:102-10.
3. Maria CC, Rubiana MM, Maria PD. Development and validation of HPLC method for the analysis of dexamethasone in microemulsions. Braz J Pharm Sci 2009;45:87-92.
4. Derle DV, Sagar BS, Rohini P. Microemulsion as a vehicle for transdermal permeation ofnimesulide. Indian J Pharm Sci 2006;68:622-5.
5. Huabing C, Xueling C, Ting W, Xiaozhi Z, Zhonghong G, Yajiang Y. A study of microemulsion systems for transdermal delivery of triptolide. J Control Release 2004;98:427-36.
6. Sukanya G, Mantray S. Review on nanoemulsions. Int J Innov Pharm Sci Res 2013;21(2):192-205.
7. Gupta PK, Pandit JK. Pharmaceutical nano technology novel nano-emulsion-high energy emulsification preparation, evaluation and application. Pharm Res 2010;3:117-38.
8. Patel SK, Zhang Y, Pollock JA, Janjic JM. Cyclooxgenase-2 inhibiting perfluoropoly (Ethylene glycol) ether theranostic nanoemulsions - in vitro study. PLoS One 2013;8(2):e55802.
9. Rajalakshmi R, Mahesh K. Critical review on nanoemulsions. Int J Innov Drug Discov 2011;1(1):1-8.
10. Lovely C, Attama AA. Current state of nanoemulsionsin drug delivery. J Biomater Nano Biotechnol 2011;2:626-39.
11. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 2011;16:354-60.
12. Han M, He CX, Fang QL, Yang XC, Diao YY, Xu DH, et al. A novel camptothecin derivative incorporated in nanocarrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo. Pharm Res 2009;26(4):926-35.
13. Posti J, Katila K, Kostiainen T. Dissolution rate limited bioavailability of flutamide and in vitro-in vivo correlation. Eur J Pharm Biopharm 2000;49:35-9.
14. Verma A, Singh MK, Kumar B. Development and characterization of flutamide containing self-micro emulsifying drug delivery system. Int J Pharm Pharm Sci 2011;3(4):60-5.
15. Abou-Taleb MF, Signey SE, Kemary ME. Sustained release flutamide from radiation cross linked poly- 4- acryl- morpholine acrylic acid hydrogels. Macromol Res 2012;20(4):407-14.
16. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug flutamide. Eur J Pharm Biopharm 2010;74:397-405.
17. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Novel ionically-crosslinked casein nanoparticles for flutamide delivery: Formulation, characterization and in vivo pharmacokinetics. Int J Nanomed 2013;8:1721-32.
18. Jeevanajyothi B, Sreelakshmi K. Design and evaluation of self-nano emulsifying drug delivery system of flutamide. J Young Pharm 2011;3(1):4-8.
19. Emami J, Tajeddin M, Ahmadi F. Preparation and in vitro evaluation of sustained-release matrix tablets of flutamide using synthetic and naturally occurring polymers. Iran J Pharm Res 2008;7(4):247-57.
20. Elkhodairy KA, Hassan MA, Afifi SA. Formulation and optimization of orodispersible tablets of flutamide. Saudi Pharm J 2014;22(1):53-61.
21. Velcheti V, Karnik S, Bardot SF, Prakash O. Pathogenesis of prostate cancer: Lessons from basic research. Ochsner J 2008;8(4):213-8.
22. Yeole BB. Trends in the prostate cancer incidence in India. Asian Pac J Cancer Prev 2008;9(1):141-4.
23. Benedettini E, Nguyen P, Loda M. The pathogenesis of prostate cancer: From molecular to metabolic alterations. Diagn Histopathol (Oxf) 2008;14(5):195-201.
24. Mahmoud AM, Al-Alem U, Dabbous F, Ali MM, Batai K, et al. Zinc intake and risk of prostate cancer: Case-control study and meta-analysis. PLoS One 2016;11(11):e0165956.
25. Sandeep S, Raguvaran R, Rajkumar K. Factors influencing prostate cancer. Int J Pharm Pharm Sci 2014;6(6):33-5.
26. Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab 2012;13(1):120-8.
27. Chandratre SS, Dash AK. Multifunctional nanoparticles for prostate cancer therapy. AAPS Pharm Sci Tech 2014;16(1):98-107.
28. Pouton CW. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and self-micro emulsifying drug delivery systems. Eur J Pharm Sci 2000;11:93-8.
29. Suciati T, Aliyandi A, Satrialdi. Development of transdermal nanoemulsion formulation for simultaneous delivery of protein vaccine and artin-M adjuvant. Int J Pharm Pharm Sci 2014;6(6):536-46.
30. Rachmawati1 H, Yee CW, Rahma A. Formulation of tablet containing curcumin nanoemulsion. Int J Pharm Pharm Sci 2014;6(3):115-20.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.